Outcomes of Neoadjuvant vs. Palliative Treatment in Locally Advanced Pancreatic Cancer
Author Information
Author(s): Larsson Patrik, Swartling Oskar, Cheraghi Diana, Khawaja Ajnon, Soreide Kjetil, Sparrelid Ernesto, Ghorbani Poya
Primary Institution: Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Hypothesis
Patients recommended neoadjuvant chemotherapy for locally advanced pancreatic cancer have a longer overall survival compared to patients recommended palliative chemotherapy.
Conclusion
In patients with locally advanced pancreatic cancer, survival was not statistically different between those recommended for neoadjuvant chemotherapy compared with those recommended palliative chemotherapy.
Supporting Evidence
- 8803 MDT events were held during the study period.
- 162 patients had locally advanced pancreatic cancer.
- Median overall survival for neoadjuvant therapy was 11.8 months.
- Median overall survival for palliative chemotherapy was 11.0 months.
- Only 11% of patients with pancreatic cancer had locally advanced disease.
Takeaway
This study looked at patients with advanced pancreatic cancer and found that those who got chemotherapy before surgery didn't live longer than those who just got comfort care.
Methodology
An observational cohort study analyzing overall survival using Kaplan–Meier estimates and multivariable analyses.
Potential Biases
There is a risk of publication bias and selection bias due to the nature of the study design.
Limitations
The study may have selection bias and a small sample size, which could affect the statistical power.
Participant Demographics
Patients were aged ≥ 18 years, with a mix of treatment recommendations including neoadjuvant chemotherapy and palliative care.
Statistical Information
P-Value
0.226
Confidence Interval
95% CI 0.02–3.29
Statistical Significance
p = 0.226
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website